SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biomatrix (BXM) Looking Great
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John McCarthy who wrote (251)11/29/1997 8:27:00 AM
From: John McCarthy  Read Replies (1) of 569
 
Forbes Article ..............................10/20/97

Analysts project Biomatrix sales of $100 million
in 1999 and $175 million in the year 2000. This is
clearly a remarkable target for a company with
sales of just $5 million in 1996. Two similar
products exist. One of them, Hyalgan, from Italy's
Fidea Pharmaceutical, already has FDA
approval. Biomatrix's technical advantage lies in
the greater viscosity of its fluid, achieved through
a patented chemical process. A speculative buy
on dips to $34.

FYI:
forbes.com

Regards,

John
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News